2020 is different.
Release time:
2021-02-10
Different 2020
2020 years have passed, and the new coronary pneumonia that has caused panic makes this year seem particularly different.
still remember that the epidemic broke out at the beginning of the year and "closed cities" all over the country ". During the closure of the city, there are homes that cannot be returned, even if they are in the same city. Since the place where I work is more than 40 kilometers away from the city, and I am not an urban ID card, I drove to the checkpoint and was "deported" back to the company. The depression of not seeing my family made me negative. Parents at home can't use smart phones, can't make video calls, can only make phone calls every day to ask about the situation. Although they cannot meet, the hearts of their families are more closely linked.
After the emergency closure of the city, in order to better prevent and control the epidemic, the country has taken home quarantine prevention and control measures. At first, everyone thought that they could have a good rest and have a good time without going to work, but after more than two months of rest, everyone was eager to go to work. They had no income from not going to work. The family's food and clothing, mortgage, car loan and so on made you have to go to work to earn wages. Everyone's desire to go to work is getting stronger and stronger, and they all hope to resume work early.
Due to the outbreak of the epidemic, people were caught off guard. After determining the person-to-person transmission, whether it was KN95 or other types of masks, they were all robbed, and there was a situation that "a mask is hard to find. People began to worry about not buying masks and did not hesitate to spend several times the high price to buy them. There are also many people who make their own masks, thinking that as long as it is a mask. There have also been many unscrupulous vendors selling fake and shoddy masks, disrupting the market. On the one hand, the state vigorously cracked down on rectification, on the other hand, the production capacity of epidemic prevention materials kept up, and the situation quickly improved.
and the epidemic after a few months of fighting, achieved a preliminary victory, all over the country have been unsealed, enterprises and units to resume production, everyone returned to their jobs, daily before work to accept temperature and other checks, after work to abide by the company's epidemic prevention and control management system, and actively do a good job in epidemic prevention and control work.
People are also gradually adapting to life under the influence of the epidemic, consciously reducing social gathering activities, and more and more people are wearing masks when going out. My two daughters used to be particularly averse to wearing masks, not wearing them, or tearing them up. Now even the one-year-old daughter will point to her mask and say to wear a mask when she goes out.
Under the correct leadership of the country, the epidemic has been effectively prevented and controlled, while the prevention and control of the epidemic in foreign countries has been worrying, with overseas imports once becoming the most important type of increase in cases. As the year approaches and the epidemic shows signs of recurrence, I hope everyone will do a good job in epidemic prevention and let everything proceed normally. (Ma Xufeng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page